Mass spectrometry–based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells
Ian M. McDonald(University of North Carolina at Chapel Hill), Lee M. Graves(University of North Carolina at Chapel Hill)
Cited by 30
Related Papers
Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia
|Molecular Pharmacology|2010|74
Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia
|PLoS ONE|2013|73
Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
|Frontiers in Pharmacology|2023|20
BIRC6 mediates imatinib resistance independently of Mcl-1
|PLoS ONE|2017|19